Article info

Original research
Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity

Authors

  1. Correspondence to Dr Shih-Hsun Chen; Shih-Hsun.Chen{at}pfizer.com; Dr Javier Chaparro-Riggers; javier.chaparro-riggers{at}pfizer.com; Dr Shahram Salek-Ardakani; ssalekardakani{at}gmail.com
View Full Text

Citation

Chen S, Dominik PK, Stanfield J, et al
Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity

Publication history

  • Accepted August 30, 2021
  • First published October 1, 2021.
Online issue publication 
October 01, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.